Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2027
Employees
4,749
Cochlear Ltd News & Analysis
markets
The grass is always greener: Rethinking Australian vs global equities
stocks
Wide moat healthcare leader remains undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,248.20 | 13.50 | 0.15% |
| CAC 40 | 8,509.36 | 70.24 | -0.82% |
| DAX 40 | 26,128.36 | 210.25 | -0.80% |
| Dow JONES (US) | 53,343.40 | 116.38 | -0.22% |
| FTSE 100 | 10,728.04 | 7.74 | 0.07% |
| HKSE | 25,337.09 | 134.06 | -0.53% |
| NASDAQ | 26,289.71 | 355.20 | -1.33% |
| Nikkei 225 | 65,862.26 | 1,598.47 | -2.37% |
| NZX 50 Index | 13,913.69 | 47.51 | 0.34% |
| S&P 500 | 7,691.76 | 53.30 | -0.69% |
| S&P/ASX 200 | 9,040.30 | 11.70 | 0.13% |
| SSE Composite Index | 3,948.64 | 41.66 | -1.04% |